Management of Heart Failure (T Meyer, Section Editor)

Current Heart Failure Reports

, Volume 9, Issue 2, pp 117-127

First online:

Chemotherapy-Induced Cardiotoxicity

  • Amir Y. ShaikhAffiliated withUniversity of Massachusetts Memorial Medical Center
  • , Jeffrey A. ShihAffiliated withUniversity of Massachusetts Memorial Medical Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of β-blockers and angiotensin-converting enzyme inhibitors in the treatment of heart failure is well proven. The role of these medications in the prevention and treatment of chemotherapy-induced cardiotoxicity is not well established.


Doxorubicin Anthracycline Trastuzumab Heart failure Cardiomyopathy Chemotherapy Management Tyrosine kinase inhibitors TKIs Cardiotoxicity Cardio-oncology